GLP-1 receptor agonists: new treatment frontiers

Abstract

Given the early success of treating diabetes and obesity with glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their neurobiological effects, interest is mounting in identifying new clinical applications and repurposing of these drugs for the treatment of neuropsychiatric conditions. A growing body of evidence points to the potential of GLP-1RA medications for the treatment of specific mental disorders, which will open the door for continued development and refinement of this class of drugs.